LOXL3 and melanoma: Quantitative cell evaluation of LOXL3, NES, and SNAI1 immunoreactivity in dysplastic nevi, melanoma in situ, and BRAF− and BRAF+ melanoma was performed by determining the section percentage area of the epidermal region.